Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity

Rhea-AI Summary

Allurion Technologies (NYSE: ALUR) has published a study on the safety and effectiveness of the Allurion Program in adolescents with obesity. The study involved 91 adolescents aged 15-17 with an average BMI of 35.6. Key findings include:

- Average weight reduction of 13.1% four months after balloon placement
- No serious adverse events or early device removals
- Allurion Balloon offers a non-invasive treatment option for adolescent obesity

The study addresses growing concerns about adolescent obesity, which has quadrupled worldwide since 1990. The Allurion Balloon presents an alternative to invasive bariatric surgery and long-term pharmacotherapy, which raise concerns when applied to adolescents.

Positive

• Study shows 13.1% average weight reduction in adolescents after 4 months
• No serious adverse events or early device removals reported
• Allurion Balloon offers a non-invasive treatment option for adolescent obesity
• Potential for earlier intervention in obesity treatment for adolescents

Negative

• None.

Insights

Medical Research Analyst

The publication of this study marks a significant development in addressing adolescent obesity. With an average weight loss of 13.1% in just four months and no serious adverse events, the Allurion Program demonstrates promising efficacy and safety for teens aged 15-17. This non-invasive approach could fill a critical gap in treatment options, especially given the hesitancy surrounding bariatric surgery and the evidence for pharmacotherapy in this age group.

The study's results are particularly noteworthy given the rising global prevalence of adolescent obesity and its long-term health implications. The Allurion Balloon's potential as an early intervention tool could be game-changing, possibly reducing the need for more invasive treatments later in life. However, longer-term studies will be important to assess sustained weight loss and any potential impacts on adolescent growth and development.

Pediatric Endocrinologist

This study offers a ray of hope in the challenging landscape of adolescent obesity treatment. The 13.1% weight reduction without serious adverse events is impressive, especially considering the non-invasive nature of the Allurion Balloon. It's important to note that this approach includes a multidisciplinary team with specialized adolescent nutrition expertise, which likely contributes to its success.

However, we must interpret these results cautiously. The study's duration is relatively short and we need to see long-term follow-up data to understand the sustainability of weight loss and any potential effects on growth and pubertal development. Additionally, the psychological impact of this intervention on adolescents should be carefully monitored. Despite these considerations, the Allurion Program could potentially bridge the gap between lifestyle interventions and more invasive treatments for adolescent obesity.

Market Research Analyst

The publication of this study could significantly impact Allurion's market position. With adolescent obesity quadrupling worldwide, there's a substantial untapped market for safe, effective and non-invasive treatments. The Allurion Program's demonstrated efficacy in this demographic could lead to increased adoption and potentially expand the company's revenue streams.

Investors should note that this study addresses a important gap in the market, positioning Allurion between conservative lifestyle interventions and more aggressive surgical or pharmacological approaches. The lack of serious adverse events and early removals is particularly promising from a commercial perspective, as it could boost consumer confidence and healthcare provider recommendations. However, the company may face regulatory hurdles and competition from emerging pharmacotherapies. Long-term studies and real-world evidence will be critical in solidifying Allurion's market position in adolescent obesity treatment.

In a study of 91 adolescents, average weight loss was 13.1% at four months with no serious adverse events

NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study on the safety and effectiveness of the Allurion Program in adolescents.

In the study, 91 adolescents between 15 and 17 years-old with average body mass index (BMI) of 35.6 received the Allurion Balloon and the Allurion Program delivered by a multidisciplinary team, including a trained nutrition professional with adolescent experience. Average weight reduction was 13.1% four months after placement, with no serious adverse events or early device removals.

Obesity among adolescents is a growing concern. According to the World Health Organization, worldwide adult obesity has more than doubled since 1990, and adolescent obesity has quadrupled.¹ These trends are particularly concerning as living with obesity in childhood or adolescence can lead to obesity-related complications in adulthood.^2,3 Prior research has shown that while bariatric surgical procedures have become a more common treatment in adults living with obesity, patients, families, and providers are hesitant about the use of these invasive procedures in adolescents.⁴ In addition, earlier this year, the United States Preventive Services Task Force concluded that the evidence for the use of pharmacotherapy—including GLP-1 drugs—was inadequate in children and adolescents.⁵ This study affirms Allurion's belief that the Allurion Balloon represents a novel, non-invasive, safe, and effective treatment option for adolescents which can allow for earlier intervention in the treatment of obesity.

“Bariatric surgery and long-term pharmacotherapy, although effective in adults, raises concerns about invasiveness and potential risks when applied to adolescents,” said Dr. Ram Chuttani, Chief Medical Officer of Allurion. “We believe that the results of this study mark a significant milestone in the treatment of adolescent obesity, as the Allurion Balloon offers a non-invasive treatment option without several of the issues related to surgery and medications.”

Sources: 1. World Health Organization 2. Singh et al. Obes Rev. 2008;9(5):474-88. 3. Hassapidou et al. Obesity Facts. 2023;16(1):29-52. 4. Thenappan and Nadler. Current Gastroenterology Reports. 2019;21(6). 5. US Preventive Services Task Force. Interventions for High Body Mass Index in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA. 2024;332(3):226–232.

About Allurion

Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less intragastric balloon for weight loss, and offers access to the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Coach Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in the United States.

For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com

Allurion is a trademark of Allurion Technologies, Inc. in the United States and countries around the world.

Forward-Looking Statements

This press release may contain certain forward-looking statements within the meaning of the U.S. federal and state securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions and include statements regarding the ability of the Allurion Program, including the VCS, to improve patient and clinical outcomes, including outcomes in adolescents, and the impact of gLP-1s on the Allurion Program. Forward-looking statements are predictions, projections and other statements about future events that reflect the current beliefs and assumptions of Allurion’s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements in this communication, including but not limited to (i) the ability of Allurion to obtain and maintain regulatory approvals for and successfully commercialize the Allurion Program, including the Allurion Balloon and the VCS, (ii) the timing of, and results from, our clinical studies and trials, (iii) the evolution of the markets in which Allurion competes, (iv) the ability of Allurion to defend its intellectual property, (v) the impact of the COVID-19 pandemic, the Russia and Ukraine war, and the Israel-Hamas conflict on Allurion’s business, (vi) Allurion’s expectations regarding its market opportunities, including those for the VCS platform, and (vii) the risk of economic downturns and a changing regulatory landscape in the highly competitive industry in which Allurion operates. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Allurion’s Annual Report on Form 10-K filed on March 26, 2024 (as subsequently amended) and other documents filed by Allurion from time to time with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Allurion assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Allurion does not give any assurance that it will achieve its expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240905867687/en/

Global Media

Cedric Damour

PR Manager

+33 7 84 21 02 20

cdamour@allurion.com



Investor

Mike Cavanaugh, Investor Relations

ICR Westwicke

(617) 877-9641

mike.cavanaugh@westwicke.com

Source: Allurion Technologies, Inc.

FAQ

What were the results of Allurion's study on adolescent obesity treatment?

The study showed an average weight reduction of 13.1% in adolescents four months after Allurion Balloon placement, with no serious adverse events or early device removals reported.

How does the Allurion Balloon (ALUR) compare to other obesity treatments for adolescents?

The Allurion Balloon offers a non-invasive treatment option for adolescent obesity, unlike bariatric surgery which is invasive, or long-term pharmacotherapy which has inadequate evidence for use in children and adolescents according to the US Preventive Services Task Force.

What is the significance of Allurion's (ALUR) study on adolescent obesity treatment?

The study marks a significant milestone in adolescent obesity treatment, offering a non-invasive option that addresses concerns about the invasiveness and potential risks of bariatric surgery and long-term pharmacotherapy in adolescents.

What age group did Allurion's (ALUR) adolescent obesity study focus on?

The study focused on adolescents between 15 and 17 years old with an average body mass index (BMI) of 35.6.